Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Blinatumomab Therapy for Low Level Minimal Residual Disease Detected By Next-Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia
Blinatumomab, a bi-specific T-cell engager, has shown clinical benefit in minimal residual disease (MRD)-positive ( ≥0.1%) Acute Lymphoblastic Leukemia (ALL) with the BLAST trial (Gökbuget N et al., Blood. 2018) demonstrating improved overall survival (OS) and disease-free survival (DFS). We evaluated the utility of Blinatumomab in low level MRD ( (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Anush Aram Ginosyan, Karam Ashouri, Brian Michael Hom, Jennifer Hwang, Karen Resnick, Amir Ali, George Yaghmour Tags: 133 Source Type: research

131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes
Allogeneic hematopoietic cell transplant (HCT) is the only potentially curative therapy for relapsed or refractory (R/R) AML patients (pts). Due to high post-HCT relapse rates and high mortality, a minority of pts with TP53 mutations are offered HCT. Iomab-B (131I-apamistamab), an anti-CD45 radioimmunoconjugate, delivers high dose targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells while also limiting off target toxicity. With better disease control and safer access to HCT, Iomab-B led induction/conditioning can potentially improve outcomes even in pts with TP53 mutation....
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: James Foran, Boglarka Gyurkocza, Rajneesh Nath, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil H. Abhyankar, Sameem Abedin, George L Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Tags: 134 Source Type: research

Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Myelofibrosis: A Single Institution Experience
Allogeneic hematopoietic cell transplant (alloHCT) is the only potentially curative therapy for myelofibrosis (MF). Outcomes after alloHCT for MF remain dismal, with 5-year overall survival (OS) of 30-40%. Given age, comorbidities, and often advanced disease, the decision of if and when to transplant can be a challenge. We undertook this analysis to investigate our institutional experience with alloHCT for MF. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Andrew D. Trunk, Yanwen Chen, Aaron T. Gerds, Betty K. Hamilton, Ronald M. Sobecks, Sudipto Mukherjee, Sophia R Balderman, Matt E. Kalaycio, Craig S Sauter, Claudio G. Brunstein Tags: 135 Source Type: research

Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Chronic Myelomonocytic Leukemia: A Single Institution Experience
Allogeneic hematopoietic cell transplant (alloHCT) is the only potentially curative therapy for CMML. Outcomes after alloHCT for higher-risk CMML remain very poor, with 5-year overall survival (OS) of 27%. Given age, comorbidities, and often advanced disease, patient selection and the optimal timing of transplant can be challenging. We undertook this analysis to investigate our institutional experience with alloHCT for CMML. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Andrew D. Trunk, Yanwen Chen, Betty K. Hamilton, Aaron T. Gerds, Ronald M. Sobecks, Sudipto Mukherjee, Sophia R Balderman, Matt E. Kalaycio, Craig S Sauter, Claudio G. Brunstein Tags: 136 Source Type: research

Second Allogeneic Hematopoietic Cell Transplantation for Relapse in Adults with Acute Myeloid Leukemia: Outcomes and Prognostic Factors
Second allogeneic hematopoietic cell transplantation (HCT2) is potentially curative for adults with AML experiencing relapse after a first allograft (HCT1) but prognostic factors for outcomes are poorly characterized. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Megan Othus, Corentin Orvain, Naveed Ali, Filippo Milano, Chris Davis, Ryan Basom, Domitilla Baccon, Prof. Brenda M. Sandmaier, Roland B. Walter Tags: 137 Source Type: research

Impact of Wilms Tumor (WT1) Mutation on Relapse and Overall Survival in Acute Myeloid Leukemia Patients Following Allogenic Stem Cell Transplantation
Wilms tumor mutations (WT)-1 are associated with inferior survival in acute myeloid leukemia (AML); but not considered a high-risk genetic category in the European LeukemiaNet (ELN) guidelines. We compared post-allogeneic stem cell transplant (alloSCT) outcomes of WT1mut AML patients with a known poor prognostic category – TP53mut AML. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Vedavyas Gannamani, Anmol Baranwal, Kimberly J. Langer, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Vivek Roy, James Foran, Hemant Murthy, Madiha Iqbal, Jeanne Palmer, Lisa Z Sproat, Saurabh Chhabra, Nandita Khera, Mehrdad Hefazi, Abhishek Mangaonkar, Mark Tags: 138 Source Type: research

Low-Dose Decitabine Plus Venetoclax As Frontline Treatment of Acute Myeloid Leukemia
Hypomethylating agents (HMAs) (5-azacytidine or decitabine) in combination with venetoclax is standard of care in the management of elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Nevertheless, treatment toxicity, in particular bone marrow suppression remains a challenging treatment-related aspect in the care of these patients. Lower than standard dose of decitabine (low-dose decitabine) exerts its effect via induction of cellular differentiation by epigenetic regulation, thus avoiding generalized cytotoxic effects. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mareike Peters, Ciprian Jitaru, Anamaria Bancos, Adrian Bogdan Tigu, Diana Cenariu, Cristina Selicean, Vlad Moisoiu, Petra Rotariu, Maria Santa, Sabina Iluta, Rares Drula, David Kegyes, Mihnea Zdrenghea, Ciprian Tomuleasa, Gabriel Ghiaur Tags: 139 Source Type: research

Dose-Response Demonstrated for Durable Complete Remission Following High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT in Patients with R/R AML
Many older patients (pts) with relapsed or refractory (R/R) AML cannot tolerate intensive conditioning treatment and are not eligible for a potentially curative allogeneic hematopoietic cell transplant (alloHCT). 131I-apamistamab, an anti-CD45 radioimmunoconjugate, safely delivers high-dose targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells. Thus, 131I-apamistamab led induction and conditioning can provide these pts access to alloHCT. Here, we analyzed whether a dose-response relationship could be established between radiation dose to liver or bone marrow and rate of pri...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: George L Chen, Camille Abboud, Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil H. Abhyankar, James Foran, Sameem Abedin, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sa Tags: 140 Source Type: research

Single Center Evaluation of Patients with Therapy and Prior-Malignancy Related Acute Lymphoblastic Leukemia and the Use of Hematopoietic Stem Cell Transplants
Therapy-related (t-ALL) and previous malignancy-related acute lymphoblastic leukemia (pm-ALL) are a subset of ALL that arise after treatment of prior malignancy. Recent reports indicate that allogeneic hematopoietic stem cell transplantation (HCT) may yield comparable outcomes in t-ALL when compared to pm-ALL, however data remains limited in both diagnostic criteria and highest risk factors for worse prognosis. This single-center analysis aims to shed light on the unique behavior of t-ALL and pm-ALL with and without HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Jeremy S. Connors, Rima M. Saliba, Celina Ledesma, Priti Tewari, Partow Kebriaei Tags: 141 Source Type: research

Factors Predicting Survival in Patients with TP53-Mutated Myeloid Neoplasms Following Allogeneic Stem Cell Transplant
Allogeneic stem cell transplant (alloSCT) is considered the therapeutic modality of choice for patients with TP53 mutated (TP53mut) myeloid neoplams (MN). However, outcomes remain poor and factors associated with post-alloSCT survival, in this high-risk cohort, are not known. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Anmol Baranwal, Kimberly J. Langer, Vedavyas Gannamani, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Vivek Roy, James Foran, Hemant Murthy, Madiha Iqbal, Jeanne Palmer, Lisa Z Sproat, Saurabh Chhabra, Nandita Khera, Mehrdad Hefazi, Abhishek Mangaonkar, Mark Tags: 142 Source Type: research

Outcomes of Matched Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis
Immunosuppressive therapy and matched-related allogenic hematopoietic stem cell transplantation (HCT) are considered standard treatment for severe aplastic anemia (AA). When a fully matched sibling donor (MSD) is unavailable, a matched unrelated donor (MUD) or haploidentical HCT is an alternative approach. This systematic review and meta-analysis aimed to explore the outcomes of MUD or haploidentical HCT in severe AA. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Moazzam Shahzad, Ahmad Basharat, Muhammad Fareed Khalid, Jawad Noor, Salman J Khan, Muftah Mahmud, Muhammad Kashif Amin, Ammad Naeem, Iqra Anwar, Mohammad Ammad Ud Din, Michael V Jaglal Tags: 194 Source Type: research

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Vexas Syndrome: A Systematic Review and Meta-Analysis
Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome presents as an auto-inflammatory disorder with overlapping hematological and rheumatological features. It is caused by mutation in UBA1 and is often refractory to treatment. Corticosteroids and Janus Kinase (JAK) inhibitors are being used for symptomatic treatment. Here, we review the literature for the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with VEXAS Syndrome. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Moazzam Shahazad, Waleed Ahmed Mir, Muhammad Fareed Khalid, Sakina Abbas, Iqra Anwar, Muhammad Kashif Amin, Atif Butt, Michael V Jaglal Tags: 195 Source Type: research

Preclinical Specificity and Activity of CABA-201, a Fully Human 41BB Containing CD19 CAR T Therapy for Treatment-Resistant Autoimmune Disease
Autoimmune diseases (AD) are common, with an incidence of 1 in 10 individuals. Most AD have standardized treatment regimens, but no curative therapy. Treatment consists of immunosuppressive therapy with associated toxicity. Targeted biologic therapies directed at cytokine pathways, costimulatory molecules, and B cells are also utilized but are limited by need for frequent infusions and high cost and incidence of adverse events. There is increasing evidence that B cells play a central role in AD pathogenesis, based upon responsiveness to B cell depletion with antibody-based therapeutics, but responses are typically transien...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Joel Weinthal, Jason Peng, Andrea Alvarado, Hangameh Cassim, Willis Jonathan, Julia SantaMaria, Ashley Martynchuk, Victoria Stratton, Steven Wong, Darshil Patel, Chien-Chung Chen, Yan Li, Gwendolyn Binder, Rebecca Dryer-Minnerly, Samik Basu, Jinmin Lee Tags: 196 Source Type: research

IFNg SMC: A New Approach to Mesenchymal Stem Cell Therapy
Cellular therapies have demonstrated great promise and exceptional safety profiles in clinical trials. However, except for a subset of autologous therapies, manufactured at small scale, regulatory approval and wide commercial success has been lacking for allogeneic products for treatment of large patient populations. Issues impeding success include high costs of production, low scalability, low or variable control of manufacturing parameters, causing lot-to-lot variation, and complex cold-chain logistics. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Erik J. Woods, Hannah M. Miller, Brian H. Johnstone Tags: 197 Source Type: research

Success of Centralized Manufacturing of CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML
We describe feasibility of centralized manufacturing for CD33 CAR T-cell products (CD33CART) on the dose-escalation part of a multicenter Phase I/II clinical trial in children and adolescents/young adults (AYA) with r/r AML (NCT03971799). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Brian Bowser, Xiaoyi Yang, John Roach, Julie Blake, Kate Donnelly, Brenna Paskey, Heidi VanBockel, Bonnie Yates, Chloe Hoang, Sarah K Tasian, Katherine Tarlock, Susanne H.C. Baumeister, Emily M. Hsieh, Michael R. Verneris, Hati K Kobusingye, Allison Weiss Tags: 198 Source Type: research